Leerink Partnrs Analysts Lift Earnings Estimates for LXRX

Key Points

• Leerink Partners raised their earnings estimates for Lexicon Pharmaceuticals, projecting an EPS of ($0.05) for Q3 2025, compared to a prior estimate of ($0.09).
• Lexicon Pharmaceuticals reported a EPS of $0.01 for the most recent quarter, beating analyst expectations of ($0.08) by $0.09.
• Lexicon currently has a consensus rating of "Hold" among analysts, with a consensus price target of $3.23.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Equities research analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of Lexicon Pharmaceuticals in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.66) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals' Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%. The company had revenue of $28.87 million for the quarter, compared to the consensus estimate of $4.87 million.

A number of other analysts also recently weighed in on the company. Wall Street Zen began coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a "sell" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday, June 24th. Finally, Citigroup boosted their price target on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a "buy" rating in a report on Thursday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of "Hold" and an average target price of $3.23.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX stock traded up $0.07 during midday trading on Monday, hitting $1.18. The company had a trading volume of 1,899,281 shares, compared to its average volume of 8,799,475. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.18. The stock has a market cap of $426.99 million, a price-to-earnings ratio of -3.56 and a beta of 1.17. The company's 50 day simple moving average is $0.97 and its 200 day simple moving average is $0.72.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth $28,000. Bayesian Capital Management LP acquired a new stake in Lexicon Pharmaceuticals during the fourth quarter worth about $31,000. Renaissance Technologies LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $38,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at approximately $51,000. Finally, Straight Path Wealth Management bought a new position in Lexicon Pharmaceuticals in the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.